Disc Medicine, Inc. — 2022 Form 10-K Summary
Business context and reporting period
Annual report for the fiscal year ended December 31, 2022, filed March 31, 2023. Disc Medicine is a clinical-stage biopharmaceutical company developing treatments for hematologic diseases involving heme biosynthesis and iron homeostasis. It has no approved products and has generated no product revenue.
On December 29, 2022, the company completed a reverse merger with Gemini Therapeutics; Disc’s former private-company business is the accounting predecessor. The combined company began trading as Disc Medicine (Nasdaq: IRON) on December 30. Former Disc stockholders owned approximately 74% of the combined company immediately after the merger.
Financial results and liquidity
| Metric | 2022 | 2021 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $33.4 million | $25.2 million |
| General and administrative expense | $14.0 million | $5.8 million |
| Total operating expenses / operating loss | $47.5 million | $30.9 million |
| Net loss | $46.8 million | $36.0 million |
| Operating cash used | $42.3 million | $27.5 million |
| Cash provided by financing | $149.0 million | $89.9 million |
At December 31, 2022, cash and cash equivalents were $194.6 million, versus $88.0 million a year earlier; total assets were $200.2 million and total liabilities were $23.6 million. The balance sheet reports no borrowings. Operating lease liabilities were $1.3 million, with $1.5 million of undiscounted lease payments remaining. Accumulated deficit was $112.2 million. Profit margins are not meaningful given the absence of revenue.
2022 financing included $53.5 million from a pre-merger share financing and approximately $97.4 million of cash acquired in the merger. Management expected year-end cash to fund planned operating and capital needs for at least 12 months from the March 31, 2023 financial-statement issuance date; elsewhere it stated cash could fund operations into 2025. These are estimates dependent on development spending and other assumptions.
Material changes versus 2021
- Net loss increased by $10.9 million, as operating expenses rose $16.5 million. R&D costs increased primarily with higher staffing and DISC-0974 clinical-trial spending; G&A rose with staffing, professional fees, and $2.2 million of costs related to an abandoned planned financing.
- Cash used in operations rose $14.7 million. Financing inflows included the Gemini merger and pre-closing financing; the preferred-stock financing that supported 2021 cash inflows was converted into common stock in the merger.
- Other income/expense improved by $5.7 million, largely because the Roche-related derivative liability generated a much smaller fair-value expense in 2022 than in 2021 and was settled through issuance of 482,313 shares at the merger.
Pipeline, outlook, and key risks
- Bitopertin: Phase 2 BEACON trial in EPP/XLP began in Australia in July 2022, with interim data expected in the first half of 2023. U.S. Phase 2 AURORA in EPP began in October 2022, with topline data expected by year-end 2023. An NIH-sponsored DBA trial was expected to begin by mid-2023. These are forward-looking expectations, not reported results.
- DISC-0974: Phase 1 in healthy volunteers was completed in June 2022; results showed tolerability and evidence of target engagement, iron mobilization, and augmented erythropoiesis. Phase 1b/2 trials for myelofibrosis anemia and non-dialysis-dependent CKD anemia began in 2022 and February 2023, respectively; interim data from both were expected in 2023.
- MWTX-003: FDA IND clearance was obtained in November 2022. The company planned a Phase 1 healthy-volunteer trial in the second half of 2023, initially targeting polycythemia vera. DISC-0998 remains preclinical.
- Funding and dilution: In January 2023, Disc established a $100 million at-the-market program and reported $15.0 million of gross sales through March 31. A February 2023 registered direct offering generated $62.5 million gross proceeds. The company paid Mabwell a $10.0 million upfront license fee in March 2023; the agreement also includes up to $127.5 million in development/regulatory milestones, up to $275 million in commercial milestones, and royalties.
- Principal risks: Clinical efficacy and safety remain unproven beyond early-stage data; development may be delayed or fail, and the company expects further losses and needs for capital. It relies on third parties for trials and single-source manufacturing, faces competition and regulatory and intellectual-property risks, and identifies possible liquidity disruption in financial services as a risk. The filing says significant cash was held at SVB in largely uninsured accounts but does not clearly quantify the exposure or any resulting loss.
- The audited financial statements received an unqualified opinion from Ernst & Young. Management did not assess internal control over financial reporting as of year-end, citing the late-December merger and transition; it planned its first assessment as of December 31, 2023. Management concluded disclosure controls were effective at the reasonable-assurance level.
Important facts for investors to verify
- Progress, enrollment, safety, and data timing for BEACON, AURORA, and both DISC-0974 trials; assess final data against the filing’s preliminary and projected outcomes.
- Actual cash use, updated runway, and financing needs as clinical and manufacturing spending grows; confirm the cash position and any remaining SVB exposure or recovery.
- Share dilution from the ATM, February offering and pre-funded warrants, equity plans, and potential future financing. The cover reports 18,998,025 shares outstanding on February 28, 2023, while the beneficial-ownership section uses 18,988,025; reconcile this 10,000-share discrepancy.
- Milestone, royalty, and territory terms under the Roche, AbbVie, and Mabwell licenses, including the Mabwell upfront payment and contingent obligations.
- Resolve the filing’s inconsistent MWTX-003 Phase 1 timing: the business outlook says second half of 2023, while a risk-factor passage refers to first half of 2023.